The Saudi Food and Drug Authority (SFDA) has approved the registration of Jascayd (nerandomilast) for the treatment of adult patients with idiopathic pulmonary fibrosis (IPF).
摘自出版方的摘要
Segal 展示此标题及简短摘要仅供参考。完整报道归 Saudi Gazette 所有,可在其网站上查阅。
The Saudi Food and Drug Authority (SFDA) has approved the registration of Jascayd (nerandomilast) for the treatment of adult patients with idiopathic pulmonary fibrosis (IPF).
摘自出版方的摘要
Segal 展示此标题及简短摘要仅供参考。完整报道归 Saudi Gazette 所有,可在其网站上查阅。